Medical Grand Rounds

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.

Randall C. Starling, MD, MPH
Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Randall C. Starling, MD, MPH, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

The author has indicated that he has received grant or research support from Acorn Cardiovascular corporation, and is a consultant for Novartis.

This paper discusses therapies that are experimental or not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the authors but are not peer-reviewed.

Phillip M. Hall, MD
Consultant, Department of Nephrology and Hypertension, Director, Renal Function Lab, Renal Stone Clinic, The Cleveland Clinic

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Phillip M. Hall, MD
Consultant, Department of Nephrology and Hypertension, Director, Renal Function Lab, Renal Stone Clinic, The Cleveland Clinic

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Phillip M. Hall, MD
Consultant, Department of Nephrology and Hypertension, Director, Renal Function Lab, Renal Stone Clinic, The Cleveland Clinic

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Holly L. Thacker, MD
Head, Section of Women’s Health, Women’s Health Center; Director, Women’s Health Track, General Internal Medicine Fellowship, The Cleveland Clinic

Address: Holly L. Thacker, MD, Women’s Health Center, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Thacker has indicated that she serves on the speakers’ bureaus of the Pfizer, Wyeth-Ayerst, Eli Lilly, and Merck corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Holly L. Thacker, MD
Head, Section of Women’s Health, Women’s Health Center; Director, Women’s Health Track, General Internal Medicine Fellowship, The Cleveland Clinic

Address: Holly L. Thacker, MD, Women’s Health Center, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Thacker has indicated that she serves on the speakers’ bureaus of the Pfizer, Wyeth-Ayerst, Eli Lilly, and Merck corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Holly L. Thacker, MD
Head, Section of Women’s Health, Women’s Health Center; Director, Women’s Health Track, General Internal Medicine Fellowship, The Cleveland Clinic

Address: Holly L. Thacker, MD, Women’s Health Center, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Thacker has indicated that she serves on the speakers’ bureaus of the Pfizer, Wyeth-Ayerst, Eli Lilly, and Merck corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Erwin B. Montgomery, Jr., MD
Co-Director, Center for Functional and Restorative Neuroscience; Departments of Neurology and Neuroscience, Lerner Research Center, The Cleveland Clinic

Address: Erwin B. Montgomery, Jr., MD, Departments of Neurology and Neuroscience, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Montgomery has indicated that he has received grant or research support from Medtronic, Inc., serves as a consultant for Medtronic, Inc., and is on the speakers’ bureaus of the Medtronic, GlaxoSmithKline, and Pharmacia corporations.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Erwin B. Montgomery, Jr., MD
Co-Director, Center for Functional and Restorative Neuroscience; Departments of Neurology and Neuroscience, Lerner Research Center, The Cleveland Clinic

Address: Erwin B. Montgomery, Jr., MD, Departments of Neurology and Neuroscience, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Montgomery has indicated that he has received grant or research support from Medtronic, Inc., serves as a consultant for Medtronic, Inc., and is on the speakers’ bureaus of the Medtronic, GlaxoSmithKline, and Pharmacia corporations.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Erwin B. Montgomery, Jr., MD
Co-Director, Center for Functional and Restorative Neuroscience; Departments of Neurology and Neuroscience, Lerner Research Center, The Cleveland Clinic

Address: Erwin B. Montgomery, Jr., MD, Departments of Neurology and Neuroscience, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Montgomery has indicated that he has received grant or research support from Medtronic, Inc., serves as a consultant for Medtronic, Inc., and is on the speakers’ bureaus of the Medtronic, GlaxoSmithKline, and Pharmacia corporations.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Joseph V. Nally, Jr., MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: Joseph V. Nally, Jr., MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Joseph V. Nally, Jr., MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: Joseph V. Nally, Jr., MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Joseph V. Nally, Jr., MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: Joseph V. Nally, Jr., MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.